457 related articles for article (PubMed ID: 30563098)
1. Recent Advances in Oncolytic Virotherapy and Immunotherapy for Glioblastoma: A Glimmer of Hope in the Search for an Effective Therapy?
Stepanenko AA; Chekhonin VP
Cancers (Basel); 2018 Dec; 10(12):. PubMed ID: 30563098
[TBL] [Abstract][Full Text] [Related]
2. The need for paradigm shift: prognostic significance and implications of standard therapy-related systemic immunosuppression in glioblastoma for immunotherapy and oncolytic virotherapy.
Stepanenko AA; Sosnovtseva AO; Valikhov MP; Chernysheva AA; Abramova OV; Naumenko VA; Chekhonin VP
Front Immunol; 2024; 15():1326757. PubMed ID: 38390330
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic viruses as a promising therapeutic strategy against the detrimental health impacts of air pollution: The case of glioblastoma multiforme.
Kazemi Shariat Panahi H; Dehhaghi M; Lam SS; Peng W; Aghbashlo M; Tabatabaei M; Guillemin GJ
Semin Cancer Biol; 2022 Nov; 86(Pt 3):1122-1142. PubMed ID: 34004331
[TBL] [Abstract][Full Text] [Related]
4. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
[TBL] [Abstract][Full Text] [Related]
5. What next for newly diagnosed glioblastoma?
Domingo-Musibay E; Galanis E
Future Oncol; 2015; 11(24):3273-83. PubMed ID: 26558493
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic concentrations of anti-epileptic drugs do not inhibit the activity of the oncolytic adenovirus Delta24-RGD in malignant glioma.
de Jonge J; Berghauser Pont LM; Idema S; Kloezeman JJ; Noske D; Dirven CM; Lamfers ML
J Gene Med; 2013; 15(3-4):134-41. PubMed ID: 23606319
[TBL] [Abstract][Full Text] [Related]
7. Recurrent Glioblastoma Treated with Recombinant Poliovirus.
Desjardins A; Gromeier M; Herndon JE; Beaubier N; Bolognesi DP; Friedman AH; Friedman HS; McSherry F; Muscat AM; Nair S; Peters KB; Randazzo D; Sampson JH; Vlahovic G; Harrison WT; McLendon RE; Ashley D; Bigner DD
N Engl J Med; 2018 Jul; 379(2):150-161. PubMed ID: 29943666
[TBL] [Abstract][Full Text] [Related]
8. Low-dose oncolytic adenovirus therapy overcomes tumor-induced immune suppression and sensitizes intracranial gliomas to anti-PD-1 therapy.
Belcaid Z; Berrevoets C; Choi J; van Beelen E; Stavrakaki E; Pierson T; Kloezeman J; Routkevitch D; van der Kaaij M; van der Ploeg A; Mathios D; Sleijfer S; Dirven C; Lim M; Debets R; Lamfers MLM
Neurooncol Adv; 2020; 2(1):vdaa011. PubMed ID: 32642679
[TBL] [Abstract][Full Text] [Related]
9. The oncolytic Newcastle disease virus as an effective immunotherapeutic strategy against glioblastoma.
Cuoco JA; Rogers CM; Mittal S
Neurosurg Focus; 2021 Feb; 50(2):E8. PubMed ID: 33524945
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors.
Medikonda R; Pant A; Lim M
Adv Exp Med Biol; 2023; 1394():73-84. PubMed ID: 36587382
[TBL] [Abstract][Full Text] [Related]
11. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.
Liau LM; Ashkan K; Tran DD; Campian JL; Trusheim JE; Cobbs CS; Heth JA; Salacz M; Taylor S; D'Andre SD; Iwamoto FM; Dropcho EJ; Moshel YA; Walter KA; Pillainayagam CP; Aiken R; Chaudhary R; Goldlust SA; Bota DA; Duic P; Grewal J; Elinzano H; Toms SA; Lillehei KO; Mikkelsen T; Walbert T; Abram SR; Brenner AJ; Brem S; Ewend MG; Khagi S; Portnow J; Kim LJ; Loudon WG; Thompson RC; Avigan DE; Fink KL; Geoffroy FJ; Lindhorst S; Lutzky J; Sloan AE; Schackert G; Krex D; Meisel HJ; Wu J; Davis RP; Duma C; Etame AB; Mathieu D; Kesari S; Piccioni D; Westphal M; Baskin DS; New PZ; Lacroix M; May SA; Pluard TJ; Tse V; Green RM; Villano JL; Pearlman M; Petrecca K; Schulder M; Taylor LP; Maida AE; Prins RM; Cloughesy TF; Mulholland P; Bosch ML
J Transl Med; 2018 May; 16(1):142. PubMed ID: 29843811
[TBL] [Abstract][Full Text] [Related]
12. Glioblastoma Multiforme: The Latest Diagnostics and Treatment Techniques.
Czarnywojtek A; Borowska M; Dyrka K; Van Gool S; Sawicka-Gutaj N; Moskal J; Kościński J; Graczyk P; Hałas T; Lewandowska AM; Czepczyński R; Ruchała M
Pharmacology; 2023; 108(5):423-431. PubMed ID: 37459849
[TBL] [Abstract][Full Text] [Related]
13. Current Immunotherapies for Glioblastoma Multiforme.
Huang B; Li X; Li Y; Zhang J; Zong Z; Zhang H
Front Immunol; 2020; 11():603911. PubMed ID: 33767690
[TBL] [Abstract][Full Text] [Related]
14. Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol.
Geletneky K; Huesing J; Rommelaere J; Schlehofer JR; Leuchs B; Dahm M; Krebs O; von Knebel Doeberitz M; Huber B; Hajda J
BMC Cancer; 2012 Mar; 12():99. PubMed ID: 22436661
[TBL] [Abstract][Full Text] [Related]
15. Superior infectivity of the fiber chimeric oncolytic adenoviruses Ad5/35 and Ad5/3 over Ad5-delta-24-RGD in primary glioma cultures.
Stepanenko AA; Sosnovtseva AO; Valikhov MP; Chernysheva AA; Cherepanov SA; Yusubalieva GM; Ruzsics Z; Lipatova AV; Chekhonin VP
Mol Ther Oncolytics; 2022 Mar; 24():230-248. PubMed ID: 35071746
[TBL] [Abstract][Full Text] [Related]
16. The in vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunity.
Kleijn A; Kloezeman J; Treffers-Westerlaken E; Fulci G; Leenstra S; Dirven C; Debets R; Lamfers M
PLoS One; 2014; 9(5):e97495. PubMed ID: 24866126
[TBL] [Abstract][Full Text] [Related]
17. Clinical trials using oncolytic viral therapy to treat adult glioblastoma: a progress report.
Lu VM; Shah AH; Vallejo FA; Eichberg DG; Luther EM; Shah SS; Komotar RJ; Ivan ME
Neurosurg Focus; 2021 Feb; 50(2):E3. PubMed ID: 33524946
[TBL] [Abstract][Full Text] [Related]
18. Clinical advances in oncolytic virotherapy for pediatric brain tumors.
Ghajar-Rahimi G; Kang KD; Totsch SK; Gary S; Rocco A; Blitz S; Kachurak K; Chambers MR; Li R; Beierle EA; Bag A; Johnston JM; Markert JM; Bernstock JD; Friedman GK
Pharmacol Ther; 2022 Nov; 239():108193. PubMed ID: 35487285
[TBL] [Abstract][Full Text] [Related]
19. Advances in immunotherapy for glioblastoma multiforme.
Mahmoud AB; Ajina R; Aref S; Darwish M; Alsayb M; Taher M; AlSharif SA; Hashem AM; Alkayyal AA
Front Immunol; 2022; 13():944452. PubMed ID: 36311781
[TBL] [Abstract][Full Text] [Related]
20. Emerging immunotherapies for glioblastoma.
Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
